Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients

NCT07319689 | Completed

• 1 other identifier: 36264PR13103/10/25
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.

Conditions

Predictor; Myasthenia Gravis; Thoracoscopic Thymectomy; Thymomatous; Non-Thymomatous

Outcome Measures

Primary Outcomes (1)

• Proportion of patients achieving complete stable remission

  Proportion of patients achieving complete stable remission was recorded.

  12 months post-procedure

Secondary Outcomes (1)

• Proportion of patients achieving pharmacologic remission

  12 months post-procedure

Study Arms (2)

Thymomatous Myasthenia Gravis group

Thymomatous myasthenia gravis (patients with histologically confirmed thymoma).

Other: Data collection

Non-thymomatous Myasthenia Gravis group

Non-thymomatous myasthenia gravis (patients with thymic hyperplasia or normal/ involuted thymus).

Other: Data collection

Interventions

Data collection OTHER

Data were obtained from patient files, operative notes, and electronic medical records.

Non-thymomatous Myasthenia Gravis group; Thymomatous Myasthenia Gravis group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study was a combined prospective and retrospective, observational, and comparative study conducted in the neurology and cardiothoracic departments at Tanta and Zagazig University Hospitals between January 2022 and December 2025.

You may qualify if:

• Both sexes.
• Confirmed diagnosis of Myasthenia Gravis (MG).
• Underwent Thoracoscopic thymectomy.
• Availability of complete preoperative and postoperative records, including imaging and histopathology.
• Minimum follow-up of 9 months post-surgery.

You may not qualify if:

• Patients who underwent thymectomy for indications other than MG.
• Incomplete medical records or loss to follow-up before outcome assessment.
• Patients with concomitant neuromuscular disorders other than MG

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

MeSH Terms

Conditions

Myasthenia Gravis

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Neuropsychiatry, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: December 20, 2025
• First Posted: January 6, 2026
• Study Start: January 1, 2022
• Primary Completion: December 18, 2025
• Study Completion: December 18, 2025
• Last Updated: January 6, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)